Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04836832
Status:
WITHDRAWN
Last Update Posted:
2022-06-07
First Post:
2021-03-09
Brief Title:
Acalabrutinib and Duvelisib for the Treatment of RelapsedRefractory Indolent Non-Hodgkin Lymphoma
Sponsor:
Narendranath Epperla
Organization:
Ohio State University Comprehensive Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-03-09
First Submit QC Date:
April 6 2021
Study First Post Date:
2021-04-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-06-02
Last Update Post Date:
2022-06-07
Last Update Post Date Type:
ACTUAL